Match Document Document Title
6261550 G-CSF hybrid molecules and pharmaceutical compositions  
The present invention relates to granulocyte colony-stimulating factor ("G-CSF") analogs and compositions containing such analogs which retain the three-dimensional structure of the internal core...
6254870 Thrombopoietin: IL-3 fusion protein  
The present invention relates to variants of human c-mpl ligands (thrombopoietin) with activity on hematopoietic differentiation and expansion.
6254861 Hematopoietic growth factor derived from T lymphocytes  
A T cell-derived colony stimulating factor ("TC-CSF") may be isolated from media conditioned with T lymphocyte cells. TC-CSF stimulates formation of colonies composed of granulocytes, macrophages,...
6250469 Formulations for protection of peg-interferon alpha conjugates  
The present invention provides formulations that prevent loss and damage of PEG-interferon alpha conjugates during and following lyophilization. The formulations of the present invention protect...
6248714 Methods of inhibiting binding and treating Ig-mediated responses with IL-13 receptor  
IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor methods of mediating-Ig-responses and methods for their identification are also disclosed.
6245900 Platelet production promoting agent  
The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity...
6245329 Method of inducing calcium flux in cells using mammalian thymokine protein  
Nucleic acids encoding a thymokine from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic...
6242414 Regulation of cytokine synthesis and release  
Methods of treatment and prevention of diseases associated with release of neutrophil elastase and IL-8 by administration of TFPI, and analogs of TFPI are disclosed. Methods of determining efficacy...
6238659 Agent for treating papilloma virus-positive malignant and premalignant lesions  
The present invention relates to a preparation comprising a substance influencing the cellular redox state for treating papilloma virus-positive malignant lesions.
6221348 Immune lymphokine-mediated control of Salmonellosis in swine  
A method and composition for treating swine to increase their resistance to pathogenic microorganisms are disclosed. Microbial infections may be prevented or reduced in swine populations by...
6214968 Fibroblast stimulating growth factor 1 (FsF-1) and the early detection of fibrosis  
A method for identifying individuals with a propensity for pathological fibrosis. The method involves providing a sample from an individual with a chronic inflammatory disease, contacting the...
6214540 Chemokines that inhibit immunodeficiency virus infection and methods based thereon  
The present invention relates to therapeutic compositions and methods for treating and preventing infection by an immunodeficiency virus, particularly HIV infection, using chemokine proteins,...
6207654 Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2  
There is provided a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability. The method...
6204363 Stem cell factor  
Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also...
6201072 Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties  
A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount of a hydrophobic A polymer block made of a biodegradable polyester and a minor...
6197749 Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes  
A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of...
6190655 Methods of using Flt-3 ligand for exogenous gene transfer  
Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is...
6187564 DNA encoding erythropoietin multimers having modified 5' and 3' sequences and its use to prepare EPO therapeutics  
Provided are nucleic acids encoding multimeric erythropoietin (EPO) proteins and having modifications in the 5' and 3' noncoding sequences relative to the corresponding sequences in native EPO DNA....
6183951 Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy  
The present invention provides methods based on serological and genetic markers for diagnosing clinical subtypes of Crohn's disease (CD) having characteristic responsiveness to anti-Th1 cytokine...
6180606 Compositions with enhanced osteogenic potential, methods for making the same and uses thereof  
Osteogenic compositions, and methods for preparing same, which compositions comprise a porous or semi-porous matrix, an osteogenic factor and an agent such as growth factors, nutrient factors,...
6180773 Tandem cDNAs encoding chemokines CC-1, CC-2, and CC-3  
The CC type chemokines belong to a family of polypeptides which have proven to be mediators of immune reactions, and they have recently attracted attention due to their antiviral activity with...
6180605 Composition with enhanced osteogenic potential, method for making the same and therapeutic uses thereof  
The present invention provides improved osteogenic compositions having enhanced by the sorption of growth factors, of nutrient factors, or drugs onto or into the compositions. Compositions may...
6180095 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents  
The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric prodrugs are preferably of the formula: ##STR1## wherein: L 1 is a bifunctional...
6177556 Human SCF, a splice variant thereof, its pharmaceutical use  
SCF which includes the following C-terminal sequence: Glu Ile Cys Ser Leu Leu Ile Gly Leu Thr Ala Tyr Lys Glu Leu Ser Leu Pro Lys Arg Lys Glu Thr Cys Arg Ala Ile Gln His Pro Arg Lys Asp or a...
6177543 Recombinant lymphotoxin  
Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein...
6174995 Human chemokines, CKβ4 and CKβ10/MCP-4  
Human chemokine polypeptides and DNA/(RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods...
6171584 Method of treatment with growth/differentiation factors of the TGF-β family  
The invention concerns a protein of the TGF-β family, the DNA coding therefor and a pharmaceutical composition containing such protein.
6169070 Mer receptor activation by gas6  
The translation product of the growth arrest-specific gene 6 (gas6) has been identified as an activator of the Mer receptor protein tyrosine kinase. The invention accordingly provides methods of...
6168787 Pluripotent vaccine against enveloped viruses  
The present invention is directed to compositions and methods for the induction of immune responses in mammals against enveloped animal viruses. More particularly, the invention provides vaccine...
6165783 Erythropoietin-mediated neurogenesis  
Methods are described for the production of neurons or neuronal progenitor cells. Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces...
6165459 Methods for suppressing myeloid cells with chemokines  
Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while...
6162426 Use of G-CSF to enhance the immune system in neonates  
The invention relates to the use of Granulocyte Colony Stimulating Factor (G-CSF) to enhance the immune system in neonates by increasing the Absolute Neutrophil Count and/or increasing the Fc γ ...
6162427 Combination of G-CSF with a chemotherapeutic agent for stem cell mobilization  
The invention relates to the use of G-CSF in combination with a chemotherapeutic agent (in particular, cyclophosphamide) to produce a pharmaceutical preparation for boosting the mobilization of...
6159461 Use of c-kit ligand with TNF-α and hematopoietic factors for the expansion or differentiation of hematopoietic cells  
Compositions comprising c-kit ligand, TNF-α, and a hematopoietic factor are useful to promote the expansion of peripheral blood cells or the expansion and differentiation of hematopoietic...
6159462 Uses of Wnt polypeptides  
Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation, differentiation or maintenance of a hematopoietic stem/progenitor...
6159460 Method for treating interleukin-1 mediated diseases  
The present invention provides methods for treating interleukin-1 mediated diseases including arthritis, inflammatory bowel disease, sepsis and septic shock, ischemia injury, reperfusion injury,...
6159463 Lymphocyte chemoattractant factor  
Purified DNA encoding LCF and the recombinant proteins expressed from such DNA are disclosed. In addition, the invention provides methods for suppressing an LCF-CD4 interaction and screening...
6156729 Leukemia inhibitory factor for use in modulating inflammation and pain  
A method for inhibiting and/or reducing inflammation and/or pain in an individual is provided. The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in...
6156302 Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes  
The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic...
6156300 Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof  
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
6153407 Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics  
Provided are nucleic acids encoding erythropoietin (EPO) proteins and having modifications in the 5' and 3' noncoding sequences relative to the corresponding sequences in native EPO DNA. The...
6143289 Compositions of myeloid-cell-suppressive chemokines  
Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory...
6143866 Tumor necrosis factor (TNF) inhibitor and method for obtaining the same  
At least two substantially purified tumor necrosis factor (TNF) inhibitors are disclosed which are glycoproteins that are active against TNF. The isolation of 3O kDa and 40 KDa TNF inhibitor from...
6139832 Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides  
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human chemokine beta-11 (Ck beta-11) polypeptide and a human leukocyte adhesion inhibitor-1...
6130318 hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4  
The present invention relates to novel hIL-4 mutant proteins, to processes for preparing them, and to their use as medicaments, in particular in overshooting, falsely regulated immune reactions and...
6126933 Methods of treating inflammatory bowel diseases by administering IL-11  
Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease,...
6120760 Growth/differentiation factors of the TGF-β family  
The invention provides DNA sequences encoding novel members of the TGF-β family of proteins. The TGF-β family comprises proteins which function as growth and/or differentiation factors and which...
6117422 N∇2-CSF-1(long form) and carboxy truncated fragments thereof  
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
6113900 Use of IL-2 receptor-targeted therapeutics to inhibit allograft rejection and treat autoimmune disorders  
Methods of inhibiting allograft rejection and of inhibiting B lymphocyte-mediated autoimmune diseases are provided. The methods involve the use of agents specific for the IL-2 receptor, such as...
6110459 Transplants for myocardial scars and methods and cellular preparations  
A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal...